290 related articles for article (PubMed ID: 34129177)
1. Co-occurrence of Pituitary Neuroendocrine Tumors (PitNETs) and Tumors of the Neurohypophysis.
Saeger W; von Schöning J; Flitsch J; Jautzke G; Bergmann M; Hagel C; Knappe UJ
Endocr Pathol; 2021 Dec; 32(4):473-479. PubMed ID: 34129177
[TBL] [Abstract][Full Text] [Related]
2. Multiple tumorous lesions of the pituitary gland.
Schöning JV; Flitsch J; Lüdecke DK; Fahlbusch R; Buchfelder M; Buslei R; Knappe UJ; Bergmann M; Schulz-Schaeffer WJ; Herms J; Glatzel M; Saeger W
Hormones (Athens); 2022 Dec; 21(4):653-663. PubMed ID: 35947342
[TBL] [Abstract][Full Text] [Related]
3. Overview of the 2022 WHO Classification of Pituitary Tumors.
Asa SL; Mete O; Perry A; Osamura RY
Endocr Pathol; 2022 Mar; 33(1):6-26. PubMed ID: 35291028
[TBL] [Abstract][Full Text] [Related]
4. Synchronous Multiple Pituitary Neuroendocrine Tumors of Different Cell Lineages.
Mete O; Alshaikh OM; Cintosun A; Ezzat S; Asa SL
Endocr Pathol; 2018 Dec; 29(4):332-338. PubMed ID: 30215160
[TBL] [Abstract][Full Text] [Related]
5. Neuropathology of Pituitary Adenomas and Sellar Lesions.
Kobalka PJ; Huntoon K; Becker AP
Neurosurgery; 2021 Apr; 88(5):900-918. PubMed ID: 33476394
[TBL] [Abstract][Full Text] [Related]
6. Multilineage Pituitary Neuroendocrine Tumors (PitNETs) Expressing PIT1 and SF1.
Asa SL; Mete O; Riddle ND; Perry A
Endocr Pathol; 2023 Sep; 34(3):273-278. PubMed ID: 37268858
[TBL] [Abstract][Full Text] [Related]
7. Clinical presentation and recurrence of pituitary neuroendocrine tumors: results from a single referral center in Colombia.
Jimenez-Canizales CE; Rojas W; Alonso D; Romero I; Tabares S; Veronesi Zuluaga LA; Modica R; Colao A
J Endocrinol Invest; 2023 Nov; 46(11):2275-2286. PubMed ID: 37002436
[TBL] [Abstract][Full Text] [Related]
8. Clinical, Biological, Radiological Pathological and Immediate Post-Operative Remission of Sparsely and Densely Granulated Corticotroph Pituitary Tumors: A Retrospective Study of a Cohort of 277 Patients With Cushing's Disease.
Rak B; Maksymowicz M; Pękul M; Zieliński G
Front Endocrinol (Lausanne); 2021; 12():672178. PubMed ID: 34135861
[TBL] [Abstract][Full Text] [Related]
9. The Value of ER∝ in the Prognosis of GH- and PRL-Secreting PitNETs: Clinicopathological Correlations.
Dumitriu-Stan RI; Burcea IF; Nastase VN; Ceaușu RA; Dumitrascu A; Cocosila LC; Bastian A; Zurac S; Raica M; Poiana C
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003353
[TBL] [Abstract][Full Text] [Related]
10. Overview of the 2017 WHO Classification of Pituitary Tumors.
Mete O; Lopes MB
Endocr Pathol; 2017 Sep; 28(3):228-243. PubMed ID: 28766057
[TBL] [Abstract][Full Text] [Related]
11. Pathohistological classification of pituitary tumors: 10 years of experience with the German Pituitary Tumor Registry.
Saeger W; Lüdecke DK; Buchfelder M; Fahlbusch R; Quabbe HJ; Petersenn S
Eur J Endocrinol; 2007 Feb; 156(2):203-16. PubMed ID: 17287410
[TBL] [Abstract][Full Text] [Related]
12. Differential expression levels of β-catenin are associated with invasive behavior of both functional and non-functional pituitary neuroendocrine tumor (PitNET).
Taghavi SF; Ghorbani M; Panahi M; Nazem S; Karimi M; Salimi V; Tavakoli-Yaraki M
Mol Biol Rep; 2023 Aug; 50(8):6425-6434. PubMed ID: 37326745
[TBL] [Abstract][Full Text] [Related]
13. Pituitary neuroendocrine tumors with PIT1/SF1 co-expression show distinct clinicopathological and molecular features.
Dottermusch M; Ryba A; Ricklefs FL; Flitsch J; Schmid S; Glatzel M; Saeger W; Neumann JE; Schüller U
Acta Neuropathol; 2024 Jan; 147(1):16. PubMed ID: 38228887
[TBL] [Abstract][Full Text] [Related]
14. The expression of neural cell adhesion molecule and the microenvironment of pituitary neuroendocrine tumours.
Marques P; Barry S; Carlsen E; Collier D; Ronaldson A; Grieve J; Dorward N; Mendoza N; Nair R; Muquit S; Grossman AB; Korbonits M
J Neuroendocrinol; 2021 Dec; 33(12):e13052. PubMed ID: 34708902
[TBL] [Abstract][Full Text] [Related]
15. Oxidative stress in pituitary neuroendocrine tumors: Affecting the tumor microenvironment and becoming a new target for pituitary neuroendocrine tumor therapy.
Zhou Y; Zhang A; Fang C; Yuan L; Shao A; Xu Y; Zhou D
CNS Neurosci Ther; 2023 Oct; 29(10):2744-2759. PubMed ID: 37341156
[TBL] [Abstract][Full Text] [Related]
16. Tumors of the Neurohypophysis: One Unit's Experience and Literature Review.
Borg A; Jaunmuktane Z; Dorward N
World Neurosurg; 2020 Feb; 134():e968-e978. PubMed ID: 31734425
[TBL] [Abstract][Full Text] [Related]
17. Pituitary adenomas and granular cell tumors. Incidence, cell type, and location of tumor in 100 pituitary glands at autopsy.
Tomita T; Gates E
Am J Clin Pathol; 1999 Jun; 111(6):817-25. PubMed ID: 10361519
[TBL] [Abstract][Full Text] [Related]
18. An Institutional Experience of Tumor Progression to Pituitary Carcinoma in a 15-Year Cohort of 1055 Consecutive Pituitary Neuroendocrine Tumors.
Alshaikh OM; Asa SL; Mete O; Ezzat S
Endocr Pathol; 2019 Jun; 30(2):118-127. PubMed ID: 30706322
[TBL] [Abstract][Full Text] [Related]
19. A review of multiomics platforms in pituitary adenoma pathogenesis.
Mouchtouris N; Smit RD; Piper K; Prashant G; Evans JJ; Karsy M
Front Biosci (Landmark Ed); 2022 Mar; 27(3):77. PubMed ID: 35345309
[TBL] [Abstract][Full Text] [Related]
20. Pituicytoma Associated with Acromegaly and Cushing Disease.
Marco Del Pont F; Villalonga JF; Ries-Centeno T; Arakaki N; Katz D; Cervio A
World Neurosurg; 2020 Apr; 136():78-82. PubMed ID: 31874293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
